跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 7,037 条关于
“BRAFV600E mutation”
全部
7,037
临床试验
5,507
药物
32
机构
4
资讯
1,494
2年前
European Commission Approves Encorafenib and Binimetinib Combination for BRAF V600E-Mutant NSCLC
10个月前
Ono Pharmaceutical Secures Approvals for BRAFTOVI Combination Therapy in BRAF-Mutant Colorectal Cancer
3年前
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment for BRAFV600E-Mutant Metastatic Colorectal Cancer
2个月前
Landmark NHS Approval of Dabrafenib and Brentuximab-Vedotin Combination Offers New Hope for Patients with Rare Blood Cancers
3年前
Real-world First-line Treatment Patterns and Outcomes for BRAFV600E-Mutant Metastatic Colorectal Cancer in Europe
去年
Thyroid Cancer Pipeline Shows Robust Growth with 50+ Companies Developing Novel Therapies
去年
Comprehensive Genomic Analysis Reveals Key Metastatic Pathways and Drug Targets in Thyroid Cancer
9个月前
Novel Astatine-211 Targeted Alpha Therapy Shows Promise for Radioactive Iodine-Refractory Thyroid Cancer
去年
Targeted Therapy and Immunotherapy Combination Improves Survival in Anaplastic Thyroid Cancer
去年
Targeted Therapy and Immunotherapy Combination Shows Promise in Anaplastic Thyroid Carcinoma
第 1 页,共 150 页
上一页
下一页